Remission of metastatic cervical adenocarcinoma with weekly paclitaxel

International Journal of Gynecological Cancer

Volumn 11, Issue 2, 2001, Pages 167-168

  Ota, S ^a   Sugiyama, T ^a   Ushijima, K ^a   Fujiyoshi, K ^a   Komai, K ^a   Hirai, N ^a   Nishida, T ^a   Kamura, T ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; Cervical cancer; Paclitaxel

Indexed keywords

PACLITAXEL;

ADULT; ARTICLE; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG METASTASIS; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; THORAX RADIOGRAPHY; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; UTERINE CERVICAL NEOPLASMS;

EID: 0035027616     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2001.011002167.x     Document Type: Article

References (7)

1. Prognostic factors of the uterine cervix adenocarcinoma
2. Locally advanced cervical adenocarcinoma. Is there a place for chemosurgical treatment?
3. Taxol given weekly in advanced previously treated ovarian carcinoma-a pilot study
4. Taxol is active in platinum-resistant endometrial adenocarcinoma
5. Phase 1 study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer
6. Phase II syudy of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer
7. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study